SWSebastian F. Winter

Sebastian F. Winter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sebastian F. Winter has a total of 149 co-authors. Here are the top co-authors by number of shared publications:

  • Jorg Dietrich

    Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Boston, Massachusetts, United States

    9 shared publications
  • Eugene J. Vaios

    Department of Radiation Oncology, Duke University Medical Center, Durham, USA

    4 shared publications
  • Jorg Dietrich

    Division of Neuro-Oncology, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    4 shared publications
  • Action Amos

    International Bureau for Epilepsy, African Region Blantyre Malawi

    3 shared publications
  • Franziska Loebel

    From the Massachusetts General Hospital Cancer Center (S.F.W., E.J.V., P.K., J.D.) and Center for Neuro-Oncology, Dana-Farber Cancer Institute (E.Q.L.), Harvard Medical School; Division of Neuro-Oncology, Department of Neurology (S.F.W., E.J.V., P.K., J.D.), and Department of Radiation Oncology (H.A.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurosurgery (S.F.W., F.L.), Charité Universitatsmedizin Berlin, corporate member of Freie Universität Berlin,...

    3 shared publications
  • Helen A. Shih

    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, USA

    3 shared publications

Latest Publications

  • Open Access

    Value of artificial intelligence in neuro-oncology

    by Sebastian Voigtlaender, Thomas A Nelson, Philipp Karschnia, Eugene J Vaios, Michelle M Kim, Philipp Lohmann, Norbert Galldiks, Mariella G Filbin, Shekoofeh Azizi, Vivek Natarajan, et al.


  • Meaningful work in peril? Preserving self-efficacy in the age of artificial intelligence

    by Helen M. E. Winter, A. Marco Turk, Sebastian F. Winter


  • Seizure risk factors and management approaches in patients with brain metastases

    by Eugene J Vaios, Spencer Maingi, Kristen Batich, Sebastian F Winter, Jorg Dietrich, Trey Mullikin, Scott R Floyd, John P Kirkpatrick, Zachary J Reitman, Katherine B Peters

    A significant proportion of patients with brain metastases experience a seizure event during their disease course, which can impact morbidity and long-term outcomes. A host of factors elevate the risk for seizures in patients with brain metastases, including patient factors, metabolic imbalances, tumor burden, and treatment modality. While reducing tumor burden via local and systemic therapies remains a critical component to mitigating seizure events, select patients may remain at risk. The use of prophylactic anti-seizure medications may be warranted in a subset of patients, though several clinical trials and guidelines from medical societies currently recommend against prophylactic use. Variability in the use of prophylactic anti-seizure medications in clinical practice underscores the need to update our current understanding of seizure risk in the era of multi-modality treatment and to identify opportunities to improve risk stratification and management. Herein, we provide a comprehensive literature review summarizing the current standard for seizure management in patients with brain metastases and assess the impact of multi-modal therapies on seizure risk. We additionally highlight gaps in the literature and present opportunities for future investigation.


  • Open Access

    Unique brain injury patterns after proton vs photon radiotherapy for WHO grade 2-3 gliomas

    by Sebastian F Winter, Melissa M Gardner, Philipp Karschnia, Eugene J Vaios, Clemens Grassberger, Marc R Bussière, Katarina Nikolic, Thanakit Pongpitakmetha, Felix Ehret, David Kaul, et al.

    Central nervous system (CNS) injury following brain-directed radiotherapy remains a major challenge. Proton radiotherapy (PRT) minimizes radiation to healthy brain, potentially limiting sequelae. We characterized CNS radiotoxicity, including radiation-induced leukoencephalopathy (RIL), brain tissue necrosis (TN), and cerebral microbleeds (CMB), in glioma patients treated with PRT or photons (XRT). Thirty-four patients (19 male; median age 39.6 years) with WHO grade 2-3 gliomas treated with partial cranial radiotherapy (XRT [n = 17] vs PRT[n = 17]) were identified and matched by demographic/clinical criteria. Radiotoxicity was assessed longitudinally for 3 years post-radiotherapy via serial analysis of T2/FLAIR- (for RIL), contrast-enhanced T1- (for TN), and susceptibility (for CMB)-weighted MRI sequences. RIL was rated at whole-brain and hemispheric levels using a novel Fazekas scale-informed scoring system. The scoring system proved reliable (ICC > 0.85). Both groups developed moderate-to-severe RIL (62%[XRT]; 71%[PRT]) within 3 years; however, XRT was associated with persistent RIL increases in the contralesional hemisphere, whereas contralesional hemispheric RIL plateaued with PRT at 1-year post-radiotherapy (t = 2.180; P = .037). TN rates were greater with PRT (6%[XRT] vs 18%[PRT]; P = ns). CMB prevalence (76%[XRT]; 71%[PRT]) and burden (mean #CMB: 4.0[XRT]; 4.2[PRT]) were similar; however, XRT correlated with greater contralesional hemispheric CMB burden (27%[XRT]; 17%[PRT]; X2 = 4.986; P = .026), whereas PRT-specific CMB clustered at the radiation field margin (X2 = 14.7; P = .002). CNS radiotoxicity is common and progressive in glioma patients. Injury patterns suggest radiation modality-specificity as RIL, TN, and CMB exhibit unique spatiotemporal differences following XRT vs PRT, likely reflecting underlying dosimetric and radiobiological differences. Familiarity with such injury patterns is essential to improve patient management. Prospective studies are needed to validate these findings and assess their impacts on neurocognitive function.


  • Mitigating treatment lag for infantile epileptic spasms syndrome in low‐ and middle‐income countries: Key recommendations from the South Asia allied IESS Research Group

    by Jitendra Kumar Sahu, Priyanka Madaan, Jithangi Wanigasinghe, Prem Chand, Sebastian F. Winter, Prakash Poudel, Kyaw Linn, Mimi L. Mynak, Kanij Fatema, Aye Mya Min Aye, et al.


  • Open Access

    National plans and awareness campaigns as priorities for achieving global brain health

    by Sebastian F Winter, Donna Walsh, Coriene Catsman-Berrevoets, Valery Feigin, Frédéric Destrebecq, Suzanne L Dickson, Matilde Leonardi, Volker Hoemberg, Cristina Tassorelli, Maria Teresa Ferretti, et al.


  • Top Cited Papers

    Artificial intelligence in neurology: opportunities, challenges, and policy implications

    by Sebastian Voigtlaender, Johannes Pawelczyk, Mario Geiger, Eugene J. Vaios, Philipp Karschnia, Merit Cudkowicz, Jorg Dietrich, Ira R. J. Hebold Haraldsen, Valery Feigin, Mayowa Owolabi, et al.

    Neurological conditions are the leading cause of disability and mortality combined, demanding innovative, scalable, and sustainable solutions. Brain health has become a global priority with adoption of the World Health Organization’s Intersectoral Global Action Plan in 2022. Simultaneously, rapid advancements in artificial intelligence (AI) are revolutionizing neurological research and practice. This scoping review of 66 original articles explores the value of AI in neurology and brain health, systematizing the landscape for emergent clinical opportunities and future trends across the care trajectory: prevention, risk stratification, early detection, diagnosis, management, and rehabilitation. AI’s potential to advance personalized precision neurology and global brain health directives hinges on resolving core challenges across four pillars—models, data, feasibility/equity, and regulation/innovation—through concerted pursuit of targeted recommendations. Paramount actions include swift, ethical, equity-focused integration of novel technologies into clinical workflows, mitigating data-related issues, counteracting digital inequity gaps, and establishing robust governance frameworks balancing safety and innovation.


  • Open Access

    Histopathologically confirmed radiation-induced damage of the brain – an in-depth analysis of radiation parameters and spatio-temporal occurrence

    by Mario R. P. Kossmann, Felix Ehret, Siyer Roohani, Sebastian F. Winter, Pirus Ghadjar, Güliz Acker, Carolin Senger, Simone Schmid, Daniel Zips, David Kaul

    Background: Radiation-induced damage (RID) after radiotherapy (RT) of primary brain tumors and metastases can be challenging to clinico-radiographically distinguish from tumor progression. RID includes pseudoprogression and radiation necrosis; the latter being irreversible and often associated with severe symptoms. While histopathology constitutes the diagnostic gold standard, biopsy-controlled clinical studies investigating RID remain limited. Whether certain brain areas are potentially more vulnerable to RID remains an area of active investigation. Here, we analyze histopathologically confirmed cases of RID in relation to the temporal and spatial dose distribution. Methods: Histopathologically confirmed cases of RID after photon-based RT for primary or secondary central nervous system malignancies were included. Demographic, clinical, and dosimetric data were collected from patient records and treatment planning systems. We calculated the equivalent dose in 2 Gy fractions (EQD22) and the biologically effective dose (BED2) for normal brain tissue (α/β ratio of 2 Gy) and analyzed the spatial and temporal distribution using frequency maps. Results: Thirty-three patients were identified. High-grade glioma patients (n = 18) mostly received one normofractionated RT series (median cumulative EQD22 60 Gy) to a large planning target volume (PTV) (median 203.9 ccm) before diagnosis of RID. Despite the low EQD22 and BED2, three patients with an accelerated hyperfractionated RT developed RID. In contrast, brain metastases patients (n = 15; 16 RID lesions) were often treated with two or more RT courses and with radiosurgery or fractionated stereotactic RT, resulting in a higher cumulative EQD22 (median 162.4 Gy), to a small PTV (median 6.7 ccm). All (n = 34) RID lesions occurred within the PTV of at least one of the preceding RT courses. RID in the high-grade glioma group showed a frontotemporal distribution pattern, whereas, in metastatic patients, RID was observed throughout the brain with highest density in the parietal lobe. The cumulative EQD22 was significantly lower in RID lesions that involved the subventricular zone (SVZ) than in lesions without SVZ involvement (median 60 Gy vs. 141 Gy, p = 0.01). Conclusions: Accelerated hyperfractionated RT can lead to RID despite computationally low EQD22 and BED2 in high-grade glioma patients. The anatomical location of RID corresponded to the general tumor distribution of gliomas and metastases. The SVZ might be a particularly vulnerable area.


  • Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens

    by Philipp Karschnia, Sylvia C. Kurz, Priscilla K. Brastianos, Sebastian F. Winter, Amanda Gordon, SooAe Jones, Michelle Pisapia, Naema Nayyar, Joerg-Christian Tonn, Tracy T. Batchelor, et al.

    Objectives: The folate-antagonist methotrexate (HD-MTX) is integral to induction chemotherapy for primary CNS lymphoma (PCNSL); however, it can be associated with leukoencephalopathy. Methylenetetrahydrofolate-reductase (MTHFR) is involved in intracellular folate depletion. We assessed whether MTHFR polymorphisms affect the risk for leukoencephalopathy. Methods: We retrospectively searched our database at the Massachusetts General Hospital for newly diagnosed PCNSL treated with HD-MTX (without radiotherapy nor intrathecal chemotherapy). Results: Among 68 PCNSL patients, MTHFR polymorphisms were found in 60 individuals (88.2%) including a 677C→T genotype, a 1298A→C genotype, or a combined 677C→T/1298A→C genotype. Neither MTX clearance nor response to induction therapy was affected by specific genotypes, and complete response was achieved in 72.1% of patients by HD-MTX-based induction. However, the 1298A→C genotype was associated with increased frequency and severity of leukoencephalopathy over time (odds ratio: 4.0, CI 1.5-11.4). Such genotype predicted treatment-induced leukoencephalopathy with a sensitivity of 71.0% and a specificity of 62.2% (AUC: 0.67, CI 0.5-0.8; p=0.019). While progression-free survival did not differ in genotype-based subgroups, overall survival was lower for the 1298A→C genotype. Discussion: The MTHFR 1298A→C genotype may serve to identify PCNSL patients at elevated risk for HD-MTX-induced leukoencephalopathy. This appears to translate into reduced survival, potentially due to decreased functional status.


  • Mitigating Radiotoxicity in the Central Nervous System: Role of Proton Therapy

    by Sebastian F. Winter, Eugene J. Vaios, Helen A. Shih, Clemens Grassberger, Michael W. Parsons, Melissa M. Gardner, Felix Ehret, David Kaul, Wolfgang Boehmerle, Matthias Endres, et al.

    Opinion statement Central nervous system (CNS) radiotoxicity remains a challenge in neuro-oncology. Dose distribution advantages of protons over photons have prompted increased use of brain-directed proton therapy. While well-recognized among pediatric populations, the benefit of proton therapy among adults with CNS malignancies remains controversial. We herein discuss the role of protons in mitigating late CNS radiotoxicities in adult patients. Despite limited clinical trials, evidence suggests toxicity profile advantages of protons over conventional radiotherapy, including retention of neurocognitive function and brain volume. Modelling studies predict superior dose conformality of protons versus state-of-the-art photon techniques reduces late radiogenic vasculopathies, endocrinopathies, and malignancies. Conversely, potentially higher brain tissue necrosis rates following proton therapy highlight a need to resolve uncertainties surrounding the impact of variable biological effectiveness of protons on dose distribution. Clinical trials comparing best photon and particle-based therapy are underway to establish whether protons substantially improve long-term treatment-related outcomes in adults with CNS malignancies.